PKノンコンパートメント解析
AUC · Cmax · Tmax · t½ · CL/F · Vz/F
PKノンコンパートメント解析
AUC · Cmax · Tmax · t½ · CL/F · Vz/F
計算はこのブラウザ内で実行されます列の順序: 時間_h, 濃度
| time_h | concentration | |
|---|---|---|
CSV / TSV を貼り付け
解析結果
図の設定
Data requirements
2時点以上と0以上の数値濃度を入力してください。
時間_h, 濃度Review before reporting
研究用途のみ。原データと解析計画で検証してください。
Check raw observations, excluded rows, model assumptions and study-specific acceptance criteria before using the result.
Transparent analysis
Inputs are processed locally in your browser. Review the calculation policy, limitations and verification approach before reporting a result.
Read the methodology →A result you can audit.
Implementation check
The workflow sorts concentration-time observations, applies linear trapezoids and exposes terminal regression fit before deriving half-life, AUC extrapolation, apparent clearance and volume.
Interpretation boundary
NCA results depend on sampling coverage, BQL rules, dose and route definitions, terminal-point selection and the suitability of log-linear extrapolation. Confirmatory work requires the approved analysis environment.
Method references
M13A Bioequivalence for Immediate-Release Solid Oral Dosage FormsU.S. FDA / ICHNoncompartmental PK parameters, terminal-phase estimation and AUC reporting context.
Linear trapezoid exposure
(10+5)/2 × 1 + (5+2.5)/2 × 1.
- Time: 0, 1, 2 h
- Concentration: 10, 5, 2.5
- Linear trapezoids
- Cmax = 10
- Tmax = 0 h
- AUC₀–last = 11.25 concentration·h
Scope: Terminal regression and extrapolated parameters need adequate later samples.
Review and correction history
12 August 2026 · Internal implementation review
AUC and terminal-phase calculation review complete. Formula behavior, unit handling, limitations and linked references were checked internally.
Independent reviewer: Not yet published. A name, relevant qualification, date and exact scope will appear here only after a real review is completed.
Source-informed and internally checked; independent scientific or regulatory validation is not claimed. Research use only.